Toll Free: 1-888-928-9744

Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 175 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2015', provides an overview of the Relapsing Remitting Multiple Sclerosis (RRMS)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Relapsing Remitting Multiple Sclerosis (RRMS) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Relapsing Remitting Multiple Sclerosis (RRMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Relapsing Remitting Multiple Sclerosis (RRMS)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Relapsing Remitting Multiple Sclerosis (RRMS) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Relapsing Remitting Multiple Sclerosis (RRMS) Overview 10 Therapeutics Development 11 Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Overview 11 Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis 12 Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Development by Companies 13 Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Investigation by Universities/Institutes 17 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Development by Companies 21 Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Investigation by Universities/Institutes 24 Relapsing Remitting Multiple Sclerosis (RRMS) - Companies Involved in Therapeutics Development 25 AbbVie Inc. 25 Actelion Ltd 26 Allozyne, Inc. 27 Amarna Therapeutics B.V. 28 Antisense Therapeutics Limited 29 Biogen, Inc. 30 Cognosci, Inc. 31 F. Hoffmann-La Roche Ltd. 32 Forward Pharma A/S 33 Genmab A/S 34 GlaxoSmithKline plc 35 Iltoo Pharma 36 Mapi Pharma Ltd. 37 MedImmune, LLC 38 Merck KGaA 39 Mitsubishi Tanabe Pharma Corporation 40 Neurotec Pharma SL 41 Novartis AG 42 Nuron Biotech, Inc. 43 Octapharma AG 44 Opexa Therapeutics, Inc. 45 RedHill Biopharma Ltd. 46 Sanofi 47 Synthetic Biologics, Inc. 48 Teva Pharmaceutical Industries Limited 49 XenoPort, Inc. 50 Zydus Cadila Healthcare Limited 51 Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics Assessment 52 Assessment by Monotherapy Products 52 Assessment by Combination Products 53 Assessment by Target 54 Assessment by Mechanism of Action 57 Assessment by Route of Administration 60 Assessment by Molecule Type 62 Drug Profiles 64 (rifabutin + clarithromycin + clofazimine) - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 aldesleukin - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 ATL-1102 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 ATXMS-1467 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 AZ-17 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 Cell Therapy for Relapsing Remitting Multiple Sclerosis - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 COG-133 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 daclizumab - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 diazoxide - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 dimethyl fumarate - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 estriol - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 Gene Therapy for Relapsing and Remitting Multiple Sclerosis - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 glatiramer acetate ER - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 GSK-239512 - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 Guanabenz - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 HR-411 - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 hydralazine - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 imilecleucel-t - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 immune globulin (human) - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 interferon beta-1b - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 interferon beta-1b - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 interferon beta-1b - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 laquinimod sodium - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 MEDI-551 - Drug Profile 102 Product Description 102 Mechanism of Action 102 R&D Progress 102 MT-1303 - Drug Profile 104 Product Description 104 Mechanism of Action 104 R&D Progress 104 ofatumumab - Drug Profile 105 Product Description 105 Mechanism of Action 105 R&D Progress 105 olesoxime - Drug Profile 110 Product Description 110 Mechanism of Action 110 R&D Progress 110 opicinumab - Drug Profile 113 Product Description 113 Mechanism of Action 113 R&D Progress 113 Pegylated Interferon-Beta-1b - Drug Profile 115 Product Description 115 Mechanism of Action 115 R&D Progress 115 ponesimod - Drug Profile 116 Product Description 116 Mechanism of Action 116 R&D Progress 116 siponimod - Drug Profile 118 Product Description 118 Mechanism of Action 118 R&D Progress 118 Small Molecule to Target CTLA4 and IFNGR for RRMS - Drug Profile 120 Product Description 120 Mechanism of Action 120 R&D Progress 120 vatelizumab - Drug Profile 121 Product Description 121 Mechanism of Action 121 R&D Progress 121 VAY-736 - Drug Profile 122 Product Description 122 Mechanism of Action 122 R&D Progress 122 XP-23829 - Drug Profile 124 Product Description 124 Mechanism of Action 124 R&D Progress 124 Relapsing Remitting Multiple Sclerosis (RRMS) - Recent Pipeline Updates 125 Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects 160 Relapsing Remitting Multiple Sclerosis (RRMS) - Discontinued Products 163 Relapsing Remitting Multiple Sclerosis (RRMS) - Product Development Milestones 165 Featured News & Press Releases 165 Feb 26, 2015: Abbvie's Ongoing Research In Neuroscience And Oncology On ZINBRYTA Will Be Featured At The 2015 American Academy Of Neurology Annual Meeting 165 Dec 17, 2014: First Patient Treated in Mapi Pharma's Phase IIa Clinical Trial of GA Depot for Relapsing Remitting Multiple Sclerosis 166 Nov 04, 2014: Genzyme Announces Enrollment of First Patient in Phase II Vatelizumab Trial in Relapsing Remitting Multiple Sclerosis 167 Sep 12, 2014: Detailed Results from Biogen Idec and AbbVie's Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA (Daclizumab High-Yield Process) 167 Sep 12, 2014: Teva Presents New Clinical Safety Data in RRMS Patients Treated with Laquinimod for Two or More Years at Joint ACTRIMS-ECTRIMS Meeting 169 Jul 31, 2014: Expanded Data on Disability and Cognitive Improvements in Phase II Study of Synthetic Biologics' Trimesta in Multiple Sclerosis to be Presented at 2014 Joint ACTRIMS-ECTRIMS Meeting 170 May 30, 2014: Genmab Announces Ofatumumab Development Plans in RRMS and NMO 170 May 23, 2014: Teva and Active Biotech to Continue with the Development of Nerventra for Multiple Sclerosis Following Confirmation of CHMP Opinion 171 Apr 29, 2014: Synthetic Biologics Reports University of California, Los Angeles Announcement Of Preliminary Positive Topline Efficacy And Safety Results From Investigator-Led Phase 2 Study Of Trimesta For Relapsing-Remitting Multiple Sclerosis 172 Apr 07, 2014: ATL1102 for MS - US Patent Allowance Extends Strong IP Position 173 Appendix 174 Methodology 174 Coverage 174 Secondary Research 174 Primary Research 174 Expert Panel Validation 174 Contact Us 174 Disclaimer 175
List of Tables
Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS), H1 2015 11 Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis, H1 2015 12 Number of Products under Development by Companies, H1 2015 14 Number of Products under Development by Companies, H1 2015 (Contd..1) 15 Number of Products under Development by Companies, H1 2015 (Contd..2) 16 Number of Products under Investigation by Universities/Institutes, H1 2015 17 Comparative Analysis by Late Stage Development, H1 2015 18 Comparative Analysis by Clinical Stage Development, H1 2015 19 Comparative Analysis by Early Stage Development, H1 2015 20 Products under Development by Companies, H1 2015 21 Products under Development by Companies, H1 2015 (Contd..1) 22 Products under Development by Companies, H1 2015 (Contd..2) 23 Products under Investigation by Universities/Institutes, H1 2015 24 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by AbbVie Inc., H1 2015 25 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Actelion Ltd, H1 2015 26 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Allozyne, Inc., H1 2015 27 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Amarna Therapeutics B.V., H1 2015 28 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Antisense Therapeutics Limited, H1 2015 29 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Biogen, Inc., H1 2015 30 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Cognosci, Inc., H1 2015 31 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 32 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Forward Pharma A/S, H1 2015 33 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Genmab A/S, H1 2015 34 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by GlaxoSmithKline plc, H1 2015 35 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Iltoo Pharma, H1 2015 36 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Mapi Pharma Ltd., H1 2015 37 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by MedImmune, LLC, H1 2015 38 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Merck KGaA, H1 2015 39 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 40 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Neurotec Pharma SL, H1 2015 41 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Novartis AG, H1 2015 42 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Nuron Biotech, Inc., H1 2015 43 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Octapharma AG, H1 2015 44 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Opexa Therapeutics, Inc., H1 2015 45 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by RedHill Biopharma Ltd., H1 2015 46 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Sanofi, H1 2015 47 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Synthetic Biologics, Inc., H1 2015 48 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 49 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by XenoPort, Inc., H1 2015 50 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Zydus Cadila Healthcare Limited, H1 2015 51 Assessment by Monotherapy Products, H1 2015 52 Assessment by Combination Products, H1 2015 53 Number of Products by Stage and Target, H1 2015 55 Number of Products by Stage and Mechanism of Action, H1 2015 58 Number of Products by Stage and Route of Administration, H1 2015 61 Number of Products by Stage and Molecule Type, H1 2015 63 Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics - Recent Pipeline Updates, H1 2015 125 Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects, H1 2015 160 Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects (Contd..1), H1 2015 161 Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects (Contd..2), H1 2015 162 Relapsing Remitting Multiple Sclerosis (RRMS) - Discontinued Products, H1 2015 163 Relapsing Remitting Multiple Sclerosis (RRMS) - Discontinued Products (Contd..1), H1 2015 164



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify